VEGFA and angiosarcoma: Vascular endothelial growth factor (VEGF), which is upregulated in angiosarcoma, can be targeted by tyrosine kinase inhibitors such as pazopanib, regorafenib, sorafenib, and anlotinib as well as monoclonal antibodies such as bevacizumab.